title: C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck.
abstract: BACKGROUND
  Synovial sarcoma is a malignant mesenchymal tumor composed of varying proportions of spindle and epithelial cell components. Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C-erb-B2, also termed HER2/neu) may contribute to the tumor phenotype and provide a new therapeutic target for this soft tissue tumor.
  
  
  METHODS
  Three head and neck, one chest wall, and seven extremity synovial sarcomas were evaluated for C-erb-B2 (HER2/neu) expression by immunohistochemistry, Western immunoblotting, and fluorescence in situ hybridization (FISH).
  
  
  RESULTS
  The head and neck cases demonstrated immunohistochemically strong positive staining, whereas tumors from other anatomic locations showed neither positive nor cytoplasmic restricted staining. Antigen-targeted antibody therapy (trastuzumab) was initiated in two patients.
  
  
  CONCLUSIONS
  These results demonstrate that C-erb-B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. The data also suggest that although synovial sarcoma of the head and neck and synovial sarcoma of the extremities have similar morphologic features, they may be clinically and mechanistically distinct entities.
authors.affiliation: Department of Pathology and Laboratory Medicine, Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Randall J
authors.initials: RJ
authors.lastname: Olsen
authors.forename: William M
authors.initials: WM
authors.lastname: Lydiatt
authors.forename: Scott A
authors.initials: SA
authors.lastname: Koepsell
authors.forename: Daniel
authors.initials: D
authors.lastname: Lydiatt
authors.forename: Sonny L
authors.initials: SL
authors.lastname: Johansson
authors.forename: Sabine
authors.initials: S
authors.lastname: Naumann
authors.forename: Julia A
authors.initials: JA
authors.lastname: Bridge
authors.forename: James R
authors.initials: JR
authors.lastname: Neff
authors.forename: Steven H
authors.initials: SH
authors.lastname: Hinrichs
authors.forename: Stefano R
authors.initials: SR
authors.lastname: Tarantolo
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015153:Blotting, Western; D002648:Child; D005260:Female; D018734:Genes, erbB-2; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013584:Sarcoma, Synovial / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab